Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3-Reference-Cited by-同舟云学术

Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3

Published:2022-01-20 Issue:9 Volume:63 Page:1401-1407
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Korsen Joshua A.,Kalidindi Teja M.,Khitrov Samantha,Samuels Zachary V.,Chakraborty Goutam,Gutierrez Julia A.,Poirier John T.,Rudin Charles M.,Chen Yu,Morris Michael J.,Pillarsetty Nagavarakishore,Lewis Jason S.

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference32 articles.

1. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

2. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling

3. Lineage plasticity in cancer: a shared pathway of therapeutic resistance;Quintanal-Villalonga;Nat Rev Clin Oncol.,2020

4. Cellular plasticity and the neuroendocrine phenotype in prostate cancer

5. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial;The Lancet Oncology;2024-08

2. The 30th Annual Prostate Cancer Foundation Scientific Retreat Report;The Prostate;2024-07-17

3. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer;Journal of Nuclear Medicine;2024-05-23

4. Prostate-Specific Membrane Antigen-Targeted Therapy in Prostate Cancer: History, Combination Therapies, Trials, and Future Perspective;Cancers;2024-04-25

5. Clinical Positron Emission Tomography/Computed Tomography;PET Clinics;2024-04